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Abstract 
Background: Opioid dependence is a chronic condition with substantial health, economic and social costs. The 
study objective was to conduct a systematic review of published health-economic models of opioid agonist therapy 
for non-prescription opioid dependence, to review the different modelling approaches identified, and to inform 
future modelling studies.
Methods: Literature searches were conducted in March 2015 in eight electronic databases, supplemented by hand-
searching reference lists and searches on six National Health Technology Assessment Agency websites. Studies were 
included if they: investigated populations that were dependent on non-prescription opioids and were receiving 
opioid agonist or maintenance therapy; compared any pharmacological maintenance intervention with any other 
maintenance regimen (including placebo or no treatment); and were health-economic models of any type.
Results: A total of 18 unique models were included. These used a range of modelling approaches, including Markov 
models (n = 4), decision tree with Monte Carlo simulations (n = 3), decision analysis (n = 3), dynamic transmission 
models (n = 3), decision tree (n = 1), cohort simulation (n = 1), Bayesian (n = 1), and Monte Carlo simulations (n = 2). 
Time horizons ranged from 6 months to lifetime. The most common evaluation was cost-utility analysis reporting cost 
per quality-adjusted life-year (n = 11), followed by cost-effectiveness analysis (n = 4), budget-impact analysis/cost 
comparison (n = 2) and cost-benefit analysis (n = 1). Most studies took the healthcare provider’s perspective. Only a 
few models included some wider societal costs, such as productivity loss or costs of drug-related crime, disorder and 
antisocial behaviour. Costs to individuals and impacts on family and social networks were not included in any model.
Conclusion: A relatively small number of studies of varying quality were found. Strengths and weaknesses relating 
to model structure, inputs and approach were identified across all the studies. There was no indication of a single 
standard emerging as a preferred approach. Most studies omitted societal costs, an important issue since the implica-
tions of drug abuse extend widely beyond healthcare services. Nevertheless, elements from previous models could 
together form a framework for future economic evaluations in opioid agonist therapy including all relevant costs and 
outcomes. This could more adequately support decision-making and policy development for treatment of non-pre-
scription opioid dependence.
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Background
Physical and psychological dependence can occur with 
any opioid drug, but the non-prescription or ‘street’ use 
of heroin presents the greatest problems to society [1]. In 
2010, the global prevalence of opioid use was estimated 
at 0.6–0.8% of the population aged 15–64 years (between 
26.4 and 36.0  million opioid users), of which approxi-
mately half, or between 13 and 21  million, were using 
heroin [2].
Illicit non-prescription opioid dependence is associ-
ated with major medical, personal and social problems, 
including increased risk of infection with human immu-
nodeficiency virus (HIV) or hepatitis C virus (HCV), 
increased risk of death due to suicide, overdose or vio-
lence, decreased quality of life, high rates of psychiatric 
co-morbidity, and involvement in criminal activity [3, 4].
It was estimated in 2008 that there are approximately 
16 million injecting drug users (IDU) worldwide and that 
3 million (18.9%) of them were living with HIV. Global 
prevalence of HCV infection among injecting drug users 
in 2010 was 46.7%, meaning that some 7.4 million inject-
ing drug users worldwide are infected with HCV and 
2.3  million injecting drug users are infected with hepa-
titis B [2].
In 2010, illicit drug use was found to be associated with 
between 99,000 and 253,000 deaths globally, with drug-
related deaths accounting for between 0.5 and 1.3% of all-
cause mortality among those aged 15–64 years [2].
Heroin addiction also has significant economic costs to 
society, resulting from the association between crime and 
opioid dependence. Many opioid-dependent individu-
als become involved in crime to support their drug use, 
but crime may also provide the money and the contacts 
to buy drugs [1]. Based on a review, the average heroin 
user is likely to engage in criminal activity for 40–60% of 
the time they are not incarcerated or not in treatment [5].
Other societal impacts result from the psychopharma-
cological effects of the drug, which may result in mistakes 
at work, lost productivity or unemployment [6]. Per-
sonal relationships may suffer or parental capacity may 
be hampered. Evidence from the United Kingdom (UK) 
shows neglect among children is correlated strongly with 
parental heroin use, and in the United States of America 
(US) parental problem drug use is one of the commonest 
reasons for children entering the care system [7].
The economic and social costs of Class A drug use were 
estimated to be £15.4  billion in 2003–2004 in England 
and Wales [6], with opioid and/or crack use account-
ing for 99%. Health and social care costs accounted for 
£557 million, implying that the majority of the costs are 
borne outside of health and social care provision.
Effective treatment for opioid dependence is available 
but is likely to be long-term or even life-long. Options 
include psychosocial/behavioural assistance, and phar-
macological interventions including opioid agonist ther-
apy. The most commonly used medications for opioid 
substitution include the opioid agonist methadone, and 
buprenorphine (with/without naloxone), a partial ago-
nist/antagonist combination; less commonly used treat-
ments include naltrexone, morphine sulphate, naloxone, 
diamorphine, and medical use of heroin [8].
Recent Cochrane reviews, as well as additional stud-
ies of maintenance treatment options, have consistently 
found opioid agonist therapy to be clinically effective 
and more cost-effective than no drug therapy in opiate-
dependent users [1], and have found no major differences 
in rates of mortality or illicit drug use achieved with these 
treatments [9].
In financially constrained health systems with finite 
resources, increasing emphasis is being placed on the abil-
ity to demonstrate that healthcare interventions are not 
only effective, but also cost-effective. Economic evalu-
ations, which use modelling techniques to consider the 
comparative clinical effects, patient values and cost of 
care of alternative options, are used by payers and health-
care policymakers to inform the decision-making process.
The emphasis when conducting an economic evalu-
ation is on including all relevant evidence on costs and 
outcomes. Given the significant impacts on society, the 
economic framework in economic evaluations of non-
prescription opioid dependence should include not only 
the direct medical costs associated with treatment and 
preventive interventions, but also costs borne by other 
areas of society such as social welfare services and the 
criminal justice system, and indirect costs associated 
with lost productivity [4].
In order to explore the ways in which previous mod-
elling studies have approached this issue, we undertook 
a systematic review of published model-based economic 
evaluations of opioid agonist therapy in treating opi-
oid dependence, including modelling of long-term costs 
and outcomes and budget impact modelling. The aim 
was to identify any ‘best practice’ methods for model-
ling approaches and the costs and outcomes considered, 
which could be used to guide and inform future health 
economic models in this area. To our knowledge, this 
is the first systematic review to examine the modelling 
approaches that have been applied in opioid agonist ther-
apy for non-prescription opioid dependence.
Methods
Search strategy
Search strategies and searches of published literature were 
designed and performed by an experienced medical librar-
ian. The searches were conducted on 17–18 March 2015 
in eight electronic databases: Medline (OvidSP); Medline 
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In-Process Citations and Daily Updates (OvidSP); Embase 
(OvidSP); the Cochrane Library (Wiley); the Cochrane 
Database of Systematic Reviews (CDSR) (Wiley); the Data-
base of Abstracts of Reviews of Effects (DARE) (Wiley); 
the Health Technology Assessment (HTA) Database 
(Wiley); and the National Health Service Economic Evalu-
ation Database (NHS EED) (Wiley). The databases were 
searched from the beginning of the database to the date of 
the search. No date or language limits were applied.
Search terms appropriate for each database were used 
for the disorder (non-prescription opioid dependence), 
interventions (any pharmacological maintenance regi-
men) and study type (health economic studies of any 
type). The detailed search strategies are presented in 
Additional file 1.
These searches were supplemented by hand searching 
of the reference lists of review papers.
In addition, general title searches were conducted, also 
on 17–18 March 2015, on the websites of HTA agencies 
in six countries. Health technology assessment (HTA) 
involves the systematic evaluation of properties, effects 
and/or impacts of health technologies and interven-
tions. It covers both the direct, intended consequences 
of technologies and interventions as well as their indi-
rect, unintended consequences, and the HTA approach 
is used to inform policy and decision-making in health 
care, especially on how best to allocate limited funds to 
health interventions and technologies. The assessment is 
conducted by interdisciplinary groups using explicit ana-
lytical frameworks, drawing on clinical, epidemiological, 
health economic and other information and methodolo-
gies. The six HTA agencies selected below are well estab-
lished and with clearly defined processes and references 
cases for economic models and were therefore were 
included in this search.
  • Australia: Pharmaceutical Benefits Advisory Com-
mittee (PBAC);
  • Canada: Canadian Agency for Drugs and Technolo-
gies in Health (CADTH);
  • England and Wales: National Institute for Health and 
Clinical Excellence (NICE);
  • Germany: Gemeinsamer Bundesausschuss (G-BA); 
Institute for Quality and Efficiency in Heath Care 
(IQWIG);
  • Scotland: Scottish Medicines Consortium (SMC);
  • Sweden: Tandvards-och lakemedelsformansver-
ket (TLV); Swedish Council on Health Technology 
Assessment (SBU).
These additional searches were intended to identify any 
additional published or unpublished material missed by 
the electronic database searches.
Inclusion and exclusion criteria
The inclusion and exclusion criteria used to select 
studies for the review are shown in Table  1. Each pub-
lication had to fulfil all the inclusion criteria and none 
of the exclusion criteria to be selected for inclusion 
in the review. Unless specifically stated otherwise, it 
was assumed that drug abuse pertained to illicit use of 
opioids.
Study selection
Citations identified by the searches were initially 
screened for eligibility against the inclusion and exclusion 
criteria using the title and (where present) the abstract 
and keywords. Each citation was classified as ‘include’, 
‘exclude’ or ‘unsure’. Full text copies were obtained for 
publications categorised as ‘include’ or ‘unsure’ at the ini-
tial screen.
The full-text publications were then screened against 
the inclusion and exclusion criteria by two independ-
ent researchers. Any disagreements were resolved by 
discussion and consensus. Publications that met all the 
inclusion criteria and none of the exclusion criteria after 
full-text review were selected for inclusion in the review. 
The reason for exclusion was recorded for all studies 
excluded after full-text review. Excluded publications are 
listed in Additional file 2.
Information on the modelling approach, perspective, 
time horizon, comparators and form of evaluation was 
extracted from each of the included studies and tabu-
lated. Additionally, data were extracted on the type of 
model used and the range of inputs for costs and out-
comes. Data extracted on cost inputs were aimed at 
addressing the question of what types of costs were used 
i.e. direct or wider societal and indirect costs, the evi-
dence sources for these types of costs and where gaps 
may exist in the evidence sources. Data on utility weights 
for health states in cost-utility analyses were aimed at 
understanding what values were available, what methods 
had been used and what gaps might exist.
Economic appraisal checklist
The model-based economic evaluations were assessed 
using an adapted form of the checklist for economic 
evaluations developed by the University of Glasgow 
[10]. The checklist consists of twelve questions in total, 
of which nine relate to the economic evaluation itself 
while the remaining questions address the applicabil-
ity of results to the local population. Therefore, only the 
nine questions relating to the quality of the economic 
evaluation were used in the present analysis. Each of the 
included studies was graded on each of the questions as 
‘yes’, ‘no’ or ‘can’t tell’ by one researcher, and the results 
tabulated.
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Results
Search results and study selection
A total of 2666 citations were identified in the elec-
tronic literature searches, which decreased to 2149 
after removal of duplicates. Hand searching of refer-
ence lists and review of HTA websites retrieved a fur-
ther 14 citations, making a total of 2163 citations. After 
initial screening, 63 of these progressed to full-text 
review.
After review of the full text, 45 publications were 
excluded for the following reasons: non-model or trial-
based analysis (n =  18); non-model-based cost analysis 
(n = 12); review articles (n = 10); HTA reports that did 
not contain new information of relevance to the review 
(n =  3); and outdated references, defined as pre-dating 
1995 (n  =  2). The reference lists of the review articles 
were hand searched for new references. Three of the 
HTA reports cited models that had already been cap-
tured by the searches and selection process. The out-
dated references were considered too old to be relevant 
or useful compared with current treatment programmes. 
This was in line with the HTA publication by Connock 
et  al. [1], which excluded the same references for the 
same reason.
A total of 18 unique models were included in the 
review. Figure  1 shows a preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) flow 
diagram for the study screening and selection process.
Summary of included studies
Twelve of the included models were reported in full-text 
publications [11–22]. Four were HTA evaluations [1, 
23–25]. Of the four HTA reports, two were economic 
models supporting NICE technology appraisal for nalox-
one, methadone and buprenorphine in maintenance 
treatment of opioid dependence, one was the Schering-
Plough manufacturer’s submission to the NICE technol-
ogy assessment (cited in Connock et al. [1]), and one was 
the SMC advice document based on the manufactur-
er’s submission by Schering-Plough for suboxone. The 
remaining two models were published only as abstracts 
[26–28].
Table  2 summarises the characteristics of the 18 
included models.
Interventions and populations considered
The interventions evaluated were established treatments 
in opioid dependence, including methadone maintenance 
treatment, buprenorphine maintenance treatment, medi-
cal heroin prescription, and buprenorphine combined 
with naloxone. Two US studies investigated the effect 
of expanding existing methadone maintenance treat-
ment programmes. Studies compared between active 
treatments (for example, methadone maintenance treat-
ment versus buprenorphine maintenance treatment), or 
between active treatment and no treatment or placebo 
(Table 2).
Table 1 Inclusion and exclusion criteria
Parameter Criteria
Population People who are dependent on non-prescription opioids and who are receiving opioid agonist therapy or maintenance therapy for 
opioid dependency
Intervention Pharmacological maintenance therapy, monotherapy or combination
 Morphine/morphine sulphate/diacetylmorphine/diamorphine (DIA)
 Buprenorphine (BUP)
 Methadone (METH)
 Codeine, dihydrocodeine
 Naloxone, naltrexone (NAL)
 Buprenorphine/naloxone (BUP/NAL)
Note naloxone may be used in combination with other treatments (morphine + naloxone)
The following operational definition will be employed for “maintenance” treatment: the treatment approach does not include a reduc-
tion or cessation of one of the above treatments as part of the approach
Comparators Any comparator regime used in maintenance therapy (including no therapy or placebo)
Outcomes Health economic models (any type including Markov, dynamic, Monte-Carlo, simulations, decision-trees etc)
Study types Cost-effectiveness (CEA), cost-utility (CUA), cost-minimisation (CMA), cost-benefit (CBA), budget impact (BIM), cost-consequence (CC)
Language English language abstracts
Timeframe Last 20 years (1995–2015)
Exclusions Studies indexed as case reports, case series, editorials and letters
English language title and abstracts only
Economic studies that do not employ modelling techniques (studies describing extrapolation of data beyond the primary clinical evi-
dence time horizon were considered to include modelling techniques. Studies based only on cost and outcomes during the course 
of a trial were excluded)
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Three of the models did not report their baseline pop-
ulation. Of those studies that did report the baseline 
population, most used a hypothetical cohort of opioid-
dependent patients (Table 2).
Evaluation type
Figure  2 summarises the evaluation types, time hori-
zons and modelling approaches in graphical form. The 
most common form of evaluation was a cost-utility 
analysis reporting the cost per quality-adjusted life-
year (QALY) gained, followed by cost-effectiveness 
analysis reporting cost per life-year gained/saved. No 
other type of evaluation was used in more than one 
study (Table 2; Fig. 2).
Cost-utility evaluation was employed in 11/18 stud-
ies, and cost-effectiveness evaluation in 4/18 studies. The 
remaining three studies included a cost-benefit evalu-
ation, a budget impact analysis, and a cost comparison 
(one study each).
Assessing studies using an economic appraisal checklist
The results of the economic appraisal checklist are 
shown in Fig. 3 and Additional file 3. The two abstracts 
are included for completeness, but the limited space 
available in an abstract is likely to have restricted their 
ability to report full information on the models and the 
assessment should therefore be interpreted with cau-
tion. Of the 16 studies reported in journals or HTA 
reports, more than half (9/16) scored ‘Yes’ on at least 
seven of the nine questions on the checklist, and almost 
all (14/16) scored ‘Yes’ on at least five of the nine ques-
tions. Only five studies scored ‘Yes’ on all nine questions 
(Fig. 3).
Country and perspective
The most commonly modelled countries were the US and 
the UK (Table 2). Eleven of the models were Canadian or 
US-based and one of the ten US studies did not explicitly 
report its perspective. Six US studies were from the per-
spective of the healthcare provider, and three from a soci-
etal perspective. The study based in Canada took a societal 
perspective by including costs associated with crime and 
considering the proportion of patients in employment [14].
Four studies used a UK National Health Service (NHS) 
perspective. Of these, three also included a societal per-
spective as a secondary analysis, although one of these 
Fig. 1 PRISMA flow diagram
Page 6 of 15Chetty et al. Addict Sci Clin Pract  (2017) 12:6 
Ta
bl
e 
2 
Su
m
m
ar
y 
of
 c
ha
ra
ct
er
is
ti
cs
 o
f i
nc
lu
de
d 
st
ud
ie
s
St
ud
y/
re
fe
r-
en
ce
s
Co
st
 y
ea
r/
cu
rr
en
cy
Co
un
tr
y
Fo
rm
 o
f t
he
 
ev
al
ua
tio
n
Pe
rs
pe
ct
iv
e 
ta
ke
n
Tr
ea
tm
en
ts
 
ev
al
ua
te
d
M
od
el
  
po
pu
la
tio
n
Ti
m
e 
ho
ri
zo
n
St
ud
y 
 
de
si
gn
a
O
ut
co
m
e 
m
ea
su
re
So
ci
et
al
 c
os
ts
H
ea
lth
 s
ta
te
s
Jo
ur
na
l-b
as
ed
 p
ub
lic
at
io
ns
Ba
rn
et
t [
11
]
19
96
 (U
S 
$)
U
S
C
EA
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
M
ET
H
 v
er
su
s 
D
ru
g-
fre
e 
tr
ea
tm
en
t
H
yp
ot
he
tic
al
 
co
ho
rt
 o
f 
10
00
 2
5 
ye
ar
 
ol
d 
he
ro
in
 
us
er
s
Li
fe
-t
im
e
M
ar
ko
v
Co
st
/L
YG
N
o
N
R
Ba
rn
et
t [
12
]
19
98
 (U
S 
$)
U
S
C
U
A
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
BM
T 
ve
rs
us
 
M
M
T
H
yp
ot
he
tic
al
 
co
ho
rt
10
 y
ea
rs
D
yn
am
ic
 
m
od
el
Q
A
LY
N
o
9 
st
at
es
 b
as
ed
 
on
 H
IV
 s
ta
tu
s 
(u
ni
nf
ec
te
d,
 
as
ym
pt
om
at
ic
 
H
IV
 +
ve
, A
ID
S)
 
an
d 
dr
ug
 u
se
r 
st
at
us
 (I
D
U
 
no
t o
n 
tx
, I
D
U
 
on
 tx
, n
on
-
us
er
)
M
as
so
n 
[1
3]
N
R 
(U
S 
$)
U
S
C
EA
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
M
M
T 
ve
rs
us
 
En
ric
he
d 
D
et
ox
Ba
se
d 
on
 1
79
 
pa
tie
nt
s 
in
 a
 
RC
T
10
 y
ea
rs
M
ar
ko
v
LY
G
 (b
as
e 
ca
se
) Q
A
LY
 
(S
A
)
N
o
A
liv
e 
an
d 
de
ad
N
eg
rin
 [1
5]
N
R/
(E
ur
o 
(€
))
Sp
ai
n
C
EA
D
ru
g 
Tr
ea
t-
m
en
t 
ce
nt
re
s
3 
M
M
T 
pr
og
ra
m
m
es
 
(h
ig
h,
 
m
ed
iu
m
, 
lo
w
 in
te
n-
si
ty
)
Ba
se
d 
on
 5
86
 
pa
tie
nt
s 
in
 d
ru
g 
tx
 
ce
nt
re
1 
ye
ar
Ba
ye
si
an
C
EA
C
 &
 C
EA
PF
N
R
N
R
Sc
ha
ck
m
an
 
[1
6]
20
10
 (U
S 
$)
U
S
C
U
A
So
ci
et
al
O
ffi
ce
-b
as
ed
 
BU
P/
N
A
L 
ve
rs
us
 n
o 
tr
ea
tm
en
t
H
yp
ot
he
tic
al
 
co
ho
rt
 o
f s
ta
-
bl
e 
pa
tie
nt
s 
on
 tr
ea
tm
en
t 
fo
r 6
 m
on
th
s
24
 m
on
th
s
Co
ho
rt
 s
im
u-
la
tio
n
Co
st
/Q
A
LY
Pa
tie
nt
 c
os
ts
In
 tx
 o
ff 
dr
ug
s, 
O
ff 
tx
 o
ff 
dr
ug
s, 
In
 tx
 o
n 
dr
ug
s, 
O
ff 
tx
 
on
 d
ru
gs
Sh
ee
rin
 [1
7]
19
99
/2
00
0 
(N
Z 
$)
N
ew
 Z
ea
la
nd
C
EA
N
ew
 Z
ea
la
nd
 
H
ea
lth
ca
re
M
M
T
H
yp
ot
he
tic
al
 
co
ho
rt
 o
f 
10
00
 ID
U
Li
fe
tim
e
M
ar
ko
v
Co
st
/L
YS
N
o
H
C
V 
+ 
ve
, n
o 
H
C
V,
 C
hr
on
ic
 
H
C
V,
 H
CC
, 
Co
m
pe
ns
at
ed
 
LC
, D
ec
om
-
pe
ns
at
ed
 L
C
, 
Li
ve
r t
ra
ns
-
pl
an
t, 
D
ea
th
St
ep
he
n 
[1
8]
20
11
 (U
S 
$)
U
S
C
U
A
So
ci
et
al
M
M
T 
ve
rs
us
 
th
eo
re
tic
al
 
co
ur
se
 o
f 
D
ee
p 
Br
ai
n 
st
im
ul
at
io
n
N
R
6 
m
on
th
s
D
ec
is
io
n 
an
al
yt
ic
al
Q
A
LY
Ye
s 
(p
ro
du
c-
tiv
ity
 lo
ss
es
, 
cr
im
e 
co
st
s)
N
A
 (d
ec
is
io
n 
tr
ee
)
Page 7 of 15Chetty et al. Addict Sci Clin Pract  (2017) 12:6 
Ta
bl
e 
2 
co
nt
in
ue
d
St
ud
y/
re
fe
r-
en
ce
s
Co
st
 y
ea
r/
cu
rr
en
cy
Co
un
tr
y
Fo
rm
 o
f t
he
 
ev
al
ua
tio
n
Pe
rs
pe
ct
iv
e 
ta
ke
n
Tr
ea
tm
en
ts
 
ev
al
ua
te
d
M
od
el
  
po
pu
la
tio
n
Ti
m
e 
ho
ri
zo
n
St
ud
y 
 
de
si
gn
a
O
ut
co
m
e 
m
ea
su
re
So
ci
et
al
 c
os
ts
H
ea
lth
 s
ta
te
s
Tr
an
 [1
9]
20
09
 (U
S 
$)
Vi
et
na
m
C
U
A
Vi
et
na
m
es
e 
H
ea
lth
 
Se
rv
ic
e
M
M
T 
ve
rs
us
 
no
n-
M
M
T
Ba
se
d 
on
 3
70
 
dr
ug
 u
se
rs
 
fro
m
 a
 c
oh
or
t 
st
ud
y
1 
ye
ar
 (5
%
 d
is
-
co
un
tin
g)
D
ec
is
io
n 
tr
ee
Ca
se
 o
f H
IV
 
av
er
te
d 
Q
A
LY
 o
f 
M
M
T 
ve
rs
us
 
no
n-
M
M
T
N
o
N
A
 (d
ec
is
io
n 
tr
ee
)
Za
ric
 [2
0]
19
98
 (U
S 
$)
U
S
C
U
A
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
Ex
pa
nd
-
in
g 
M
M
T 
pr
og
ra
m
m
e 
(H
IV
 p
re
va
-
le
nc
e 
ra
te
 o
f 
5%
 &
 4
0%
 
ve
rs
us
 1
5%
 
ba
se
lin
e)
H
yp
ot
he
tic
al
 
co
ho
rt
10
 y
ea
rs
D
yn
am
ic
 
m
od
el
Co
st
/Q
A
LY
 &
 
co
st
/L
YG
N
o
10
 s
ta
te
s 
ba
se
d 
on
 H
IV
 s
ta
tu
s 
(u
ni
nf
ec
te
d,
 
as
ym
pt
om
at
ic
 
H
IV
 +
ve
, A
ID
S)
 
an
d 
dr
ug
 u
se
r 
st
at
us
 (I
D
U
 
no
t o
n 
tx
, I
D
U
 
on
 tx
, n
on
-
us
er
) a
nd
 A
ID
 
de
at
h
Za
ric
 [2
1]
19
98
 (U
S 
$)
U
S
C
U
A
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
Ex
pa
nd
-
in
g 
M
M
T 
pr
og
ra
m
m
e 
(H
IV
 p
re
va
-
le
nc
e 
ra
te
s 
of
 5
,1
0,
20
, 
40
%
)
H
yp
ot
he
tic
al
 
co
ho
rt
10
 y
ea
rs
D
yn
am
ic
 
m
od
el
Q
A
LY
 a
nd
 L
YG
N
o
10
 s
ta
te
s 
ba
se
d 
on
 H
IV
 s
ta
tu
s 
(u
ni
nf
ec
te
d,
 
as
ym
pt
om
at
ic
 
H
IV
 +
ve
, A
ID
S)
 
an
d 
dr
ug
 u
se
r 
st
at
us
 (I
D
U
 
no
t o
n 
tx
, I
D
U
 
on
 tx
, n
on
-
us
er
) a
nd
 A
ID
 
de
at
h
Za
rk
in
 [2
2]
20
01
 (U
S 
$)
U
S
C
BA
So
ci
et
al
M
ET
H
H
yp
ot
he
tic
al
 
co
ho
rt
 o
f 1
 
m
ill
io
n 
ad
ul
t 
pa
tie
nt
s
Li
fe
tim
e
M
on
te
 C
ar
lo
 
si
m
ul
at
io
n 
m
od
el
Co
st
/b
en
efi
t 
ra
tio
Ye
s 
(p
ro
du
c-
tiv
ity
 lo
ss
es
, 
cr
im
e 
co
st
s)
H
er
oi
n 
no
n 
us
er
 &
 n
ot
 
in
 tx
, H
er
oi
n 
us
er
 a
nd
 n
ot
 
in
 tx
, I
n 
tx
, 
In
ca
rc
er
at
ed
 
he
ro
in
 u
se
r, 
In
ca
rc
er
at
ed
 
no
n-
us
er
M
ill
er
 [1
4]
N
R/
(C
an
ad
ia
n 
$)
Ca
na
da
Co
st
 C
om
pa
ri-
so
n
So
ci
et
al
M
H
PP
 v
er
su
s 
no
n-
M
H
PP
≥2
0 
ye
ar
s 
ol
d 
w
ith
 >
 5
 y
ea
r 
hi
st
or
y 
of
 
in
je
ct
in
g 
he
ro
in
, t
o 
in
je
ct
 h
er
oi
n 
at
 le
as
t d
ai
ly
, 
an
d 
to
 h
av
e 
pr
ev
io
us
ly
 
fa
ile
d 
M
M
T
5 
ye
ar
s
M
on
te
 C
ar
lo
 
si
m
ul
at
io
n 
m
od
el
To
ta
l c
os
t o
ve
r 
5 
ye
ar
s
Ye
s 
(c
rim
in
al
 
ac
tiv
ity
 
co
st
s)
N
A
Page 8 of 15Chetty et al. Addict Sci Clin Pract  (2017) 12:6 
Ta
bl
e 
2 
co
nt
in
ue
d
St
ud
y/
re
fe
r-
en
ce
s
Co
st
 y
ea
r/
cu
rr
en
cy
Co
un
tr
y
Fo
rm
 o
f t
he
 
ev
al
ua
tio
n
Pe
rs
pe
ct
iv
e 
ta
ke
n
Tr
ea
tm
en
ts
 
ev
al
ua
te
d
M
od
el
  
po
pu
la
tio
n
Ti
m
e 
ho
ri
zo
n
St
ud
y 
 
de
si
gn
a
O
ut
co
m
e 
m
ea
su
re
So
ci
et
al
 c
os
ts
H
ea
lth
 s
ta
te
s
H
TA
-s
ou
rc
ed
 m
od
el
s
A
di
 [2
3]
20
04
 (G
BP
 £
)
U
K
C
U
A
N
H
S 
& 
So
ci
et
al
N
TX
 v
er
su
s 
st
an
da
rd
 
ps
yc
ho
so
ci
al
 
ca
re
H
yp
ot
he
tic
al
 
co
ho
rt
1 
ye
ar
D
ec
is
io
n 
tr
ee
 
w
ith
 M
on
te
 
Ca
rlo
 s
im
u-
la
tio
ns
Q
A
LY
Ye
s, 
in
 a
 
se
co
nd
ar
y 
an
al
ys
is
N
A
 (d
ec
is
io
n 
tr
ee
)
Co
nn
oc
k 
[1
]
20
04
 (G
BP
 £
)
U
K
C
U
A
N
H
S 
& 
So
ci
et
al
M
M
T 
ve
rs
us
 
BM
T 
ve
rs
us
 
Pl
ac
eb
o
H
yp
ot
he
tic
al
 
co
ho
rt
1 
ye
ar
D
ec
is
io
n 
tr
ee
 
w
ith
 M
on
te
 
Ca
rlo
 s
im
u-
la
tio
ns
Q
A
LY
Ye
s, 
in
 a
 
se
co
nd
ar
y 
an
al
ys
is
N
A
 (d
ec
is
io
n 
tr
ee
)
Sc
he
rin
g-
Pl
ou
gh
 [2
4]
20
04
 (G
BP
 £
)
U
K
C
U
A
N
H
S 
& 
PS
S
M
ai
nt
en
an
ce
 
ve
rs
us
 n
o 
dr
ug
 tx
, B
U
P 
ve
rs
us
 n
o 
tx
, 
BU
P 
ve
rs
us
 
M
ET
H
N
R
1 
ye
ar
`
D
ec
is
io
n 
tr
ee
 
w
ith
 M
on
te
 
Ca
rlo
 s
im
u-
la
tio
ns
Q
A
LY
N
R
N
A
 (d
ec
is
io
n 
tr
ee
)
SM
C
 [2
5]
N
R/
(G
BP
 £
)
U
K
C
U
A
N
H
S 
& 
So
ci
et
al
BU
P/
N
A
L 
ve
r-
su
s 
M
ET
H
, 
BU
P 
or
 n
o 
tr
ea
tm
en
t
N
R
1 
ye
ar
D
ec
is
io
n 
an
al
yt
ic
al
Q
A
LY
N
R
N
R
Ab
st
ra
ct
s o
nl
y
C
la
y 
[2
6,
 2
7]
N
R/
(U
S 
$)
U
S
BI
M
U
S 
H
ea
lth
ca
re
 
pr
ov
id
er
BU
P/
N
A
L 
fil
m
 
ve
rs
us
 B
U
P/
N
A
L 
ta
bl
et
s
Pa
tie
nt
s 
in
iti
at
-
in
g 
tr
ea
tm
en
t 
fo
r o
pi
oi
d 
de
pe
nd
en
ce
5 
ye
ar
s
M
ar
ko
v 
m
od
el
Co
st
 im
pa
ct
 
co
m
pa
rin
g 
10
0%
 o
n 
BU
P/
N
A
L 
fil
m
 v
er
su
s 
10
0%
 o
n 
BU
P/
N
A
L
N
o
N
R
Fo
w
le
r [
28
]
N
R/
U
S 
($
)
U
S
C
U
A
N
R
M
M
T 
ve
rs
us
 
BM
T
H
yp
ot
he
ti-
ca
l c
oh
or
t 
of
 o
pi
oi
d-
de
pe
nd
en
t 
pr
eg
na
nt
 
w
om
en
N
R
D
ec
is
io
n 
an
al
yt
ic
al
 
m
od
el
Q
A
LY
N
R
N
R
AI
D
S 
ac
qu
ire
d 
im
m
un
od
efi
ci
en
cy
 s
yn
dr
om
e,
 B
IM
 b
ud
ge
t i
m
pa
ct
 m
od
el
, B
M
T 
bu
pr
en
or
ph
in
e 
m
ai
nt
en
an
ce
 tr
ea
tm
en
t, 
BU
P 
bu
pr
en
or
ph
in
e,
 B
U
P/
N
AL
 b
up
re
no
rp
hi
ne
-n
al
ox
on
e 
co
m
bi
na
tio
n,
 C
BA
 c
os
t-
be
ne
fit
 a
na
ly
si
s, 
CE
A 
co
st
 e
ffe
ct
iv
en
es
s 
an
al
ys
is
, C
EA
C 
co
st
-e
ffe
ct
iv
en
es
s 
ac
ce
pt
ab
ili
ty
 c
ur
ve
, C
EA
PF
 c
os
t-
eff
ec
tiv
en
es
s 
fr
on
tie
r, 
CU
A 
co
st
 u
til
ity
 a
na
ly
si
s, 
H
CC
 H
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a,
 H
CV
 h
ep
at
iti
s 
C 
vi
ru
s, 
H
IV
 h
um
an
 im
m
un
od
efi
ci
en
cy
 
vi
ru
s, 
H
TA
 h
ea
lth
 te
ch
no
lo
gy
 a
ss
es
sm
en
t, 
ID
U
 in
je
ct
in
g 
dr
ug
 u
se
r, 
LC
 L
iv
er
 C
irr
ho
si
s, 
LY
G
 li
fe
-y
ea
r g
ai
ne
d,
 M
CB
R 
m
ar
gi
na
l c
os
t-
be
ne
fit
 ra
tio
, M
ET
H
 m
et
ha
do
ne
, M
H
PP
 M
ed
ic
al
 H
er
oi
n 
Pr
es
cr
ip
tio
n 
Pr
og
ra
m
, M
M
T 
m
et
ha
do
ne
 
m
ai
nt
en
an
ce
 tr
ea
tm
en
t, 
N
A 
no
t a
pp
lic
ab
le
, N
AL
 n
al
tr
ex
on
e,
 N
H
S 
N
at
io
na
l H
ea
lth
 S
er
vi
ce
, N
R 
no
t r
ep
or
te
d,
 N
TX
 e
xt
en
de
d 
re
le
as
e 
na
ltr
ex
on
e,
 N
Z 
N
ew
 Z
ea
la
nd
, o
ut
px
 o
ut
pa
tie
nt
, P
SS
 P
er
so
na
l &
 S
oc
ia
l s
er
vi
ce
s, 
Q
AL
Y 
qu
al
ity
-
ad
ju
st
ed
 li
fe
-y
ea
r, 
RC
T 
ra
nd
om
is
ed
 c
on
tr
ol
le
d 
tr
ia
l, 
SA
 s
en
si
tiv
ity
 a
na
ly
si
s, 
SM
C 
Sc
ot
tis
h 
M
ed
ic
in
es
 C
on
so
rt
iu
m
, t
x 
tr
ea
tm
en
t, 
U
K 
U
ni
te
d 
Ki
ng
do
m
, U
S 
U
ni
te
d 
St
at
es
 o
f A
m
er
ic
a
a  
D
es
ig
n 
as
 d
es
cr
ib
ed
 b
y 
au
th
or
s
Page 9 of 15Chetty et al. Addict Sci Clin Pract  (2017) 12:6 
reported no details of the societal perspective analysis. 
All four UK models were HTA reports.
Of the three remaining models, one was from the per-
spective of Spanish drug treatment centres, one from the 
perspective of the New Zealand healthcare system, and one 
from the perspective of the Vietnamese healthcare system.
Studies conducted from a societal perspective included 
costs borne outside the healthcare system, such as out-of-
pocket costs incurred by patients, effects on employment 
and productivity, and the impact of criminal activity on 
the criminal justice system and on victims of crime.
Time horizons
The time horizons varied widely, ranging from 6 months 
to a lifetime. Seven studies had short time hori-
zons (6  months to a year), seven had time horizons of 
2–10 years, and three models had a lifetime horizon. One 
abstract did not report the time horizon used (Table  2; 
Fig. 2).
Modelling approaches
The 18 models used a range of different modelling 
approaches reported by authors. There did not seem 
Fig. 2 Modelling approaches, time horizons and evaluation types used in the included models. BIM budget impact, CBA cost-benefit analysis, CC 
cost comparison, CEA cost-effectiveness analysis, CUA cost-utility analysis
Fig. 3 Assessing studies using an economic appraisal checklist
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to be any single approach that emerged as a preferred 
standard.
The most commonly used approaches were Markov 
modelling, which was used by four of the included mod-
els, and decision tree modelling with Monte Carlo simu-
lations, which was used by three models.
Two further models used Monte Carlo simulations. 
Of the remaining nine, three were decision-analytical 
models, three were dynamic transmission models using 
epidemiological data on HIV prevalence, one used a deci-
sion tree, one used cohort simulation, and one used a 
Bayesian approach (Table 2; Fig. 2).
Decision-analysis trees are simple forms of health eco-
nomic models that aim to represent clinical pathways 
over time and allows synthesis of evidence to estimate 
costs and effectiveness. These models are best suited to 
modelling acute conditions or short-term interventions. 
However, decision-analysis trees are generally too sim-
ple to be used for the modelling of situations where there 
are multiple alternative actions (for example, treatment 
pathways, drug options) that are encountered in complex 
or chronic conditions (such as long-term management 
of addiction) or in cases where events may be repeated 
(such as treatment cycles).
Markov models are particularly suited to model-
ling repeated events and/or progression of disease. In 
Markov models, there are a finite set of health states (for 
example, in treatment, illicit drug user, non-user not on 
treatment) and individuals move between these health 
states over a discrete time period, known as a Markov 
cycle and according to a set of transition probabilities 
(describing the probability of moving from one health 
state to another). By attaching costs and outcomes to the 
health states, and running the model over a number of 
cycles, the long term costs and outcomes for hypotheti-
cal cohorts can be estimated. In reality, the transitions/
probabilities may vary based on individual patient treat-
ment history, and Monte Carlo simulations may be used. 
These simulations use repeated random calculations to 
obtain a distribution of a particular outcome and take 
account of different treatment histories or varying transi-
tion probabilities.
Outcomes measures and data sources
The data used in the models for outcomes and resource 
use were mainly derived from published literature, clini-
cal trials, meta-analyses or indirect comparisons. The 
budget impact analysis used a health claims database 
(Table 2).
For those studies that reported details of the clinical 
outcomes used as model inputs, the choice of outcomes 
used depended on the scope of the economic evaluations. 
In all cases outcomes associated with maintenance 
treatment were either based on impacts on mortality, 
retention in the maintenance programme or successful 
detoxification and cessation of the maintenance treat-
ment (Additional file 4). Other clinical outcomes/clinical 
effectiveness outcomes used were related to whether an 
individual was taking illicit drugs while on maintenance 
treatment, or while off treatment. Five economic evalua-
tions considered the impact of needle-sharing and sexual 
behaviour of IDU on the spread of HIV, acquired immu-
nodeficiency syndrome (AIDS) and HCV disease [12, 17, 
19–21].
The impact of disease and treatment on quality of life is 
an important indicator of outcomes. When this is com-
bined with clinical outcomes such as life-years gained, 
QALYs can be calculated. This outcome measure is rec-
ommended by HTA authorities [29–32]. The results of 
this review highlight the lack of evidence in this area of 
modelling. Additional file  5 summarises the sources of 
utility data used in the models reviewed. While utility 
weights are reported for HIV, AIDS and HCV, these are 
not specific to individuals with heroin abuse. Of the 11 
studies which used a cost-utility approach and QALYs, 
four economic evaluations derived utility weights from a 
UK panel study which used general population members 
to make valuations of given health states using a standard 
gamble method (an approach recommended by NICE). 
One economic evaluation used mapping of a generic 
psychometric scale to QALY-based estimates [19]. For 
the remaining studies, assumptions were made based on 
plausible estimates in other diseases.
Costs included in the economic evaluations are sum-
marised in Additional file 6. These included direct medi-
cal costs, which comprised all consumption of resources 
resulting from maintenance treatment (such as drug 
costs, healthcare resources); and direct non-medical 
costs such as staff costs, capital and building costs. The 
far-reaching consequences of heroin use, namely wider 
societal costs such as the costs of crime, employment, 
and support services have been included in only a lim-
ited number of studies. Only one study included costs 
to patients such as transport costs and their time spent 
travelling to and from treatment centres. The studies 
that included societal costs in the primary analysis var-
ied widely in the type of costs they included; Schackman 
et  al. [16] included only patient costs (travel, visit time 
and transport costs), Miller et al. [14] included the costs 
of criminal activity; Zarkin et  al. [22] included criminal 
costs and productivity; and Stephen et  al. [18] included 
criminal costs and productivity costs for both victim and 
crime perpetrator. A further two studies included societal 
costs as part of an additional analysis: for both, the costs 
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included were criminal justice service costs [1, 23]. One 
further study mentioned an additional analysis including 
societal costs but reported no details [25].
Figure  4 summarises the outcome measures used in 
the studies and whether societal costs were included in 
the primary analysis. Only four studies included societal 
costs in the primary analysis [14, 16, 18, 22]. The most 
commonly used outcome measure was the QALY.
Sensitivity analyses
A range of different types of sensitivity analyses have 
been reported in existing models in order to test the 
robustness of results. Deterministic and probabilistic 
analyses have been used.
In general, the results from the models did not vary 
significantly for the parameters tested in the vari-
ous forms of sensitivity analyses, and ICERs usually 
remained within cost-effectiveness thresholds. However, 
the parameters which did impact on the results included 
treatment completion rates, health-related quality of life, 
and costs associated with criminal justice services.
Discussion
Opioid dependence is typically a chronic condition with 
a dynamic and variable course. Individuals may have 
periods of illicit drug use interspersed with periods of 
treatment and periods of abstinence, and outcomes 
vary greatly from one individual to another. Opioid 
dependence also has complex effects on wider society, 
for example on the criminal justice system and victims 
of crime, so economic models should aim to capture 
these aspects in order to reflect the decision-making 
framework.
To our knowledge, this systematic review is the first to 
evaluate economic modelling studies conducted in opioid 
agonist therapy for non-prescription opioid dependence.
Several different modelling approaches have been 
reported, each with its own strengths and limitations. 
Decision-tree models typically accepted by HTA bod-
ies are simple to construct and useful where short time 
horizons are appropriate and the estimation of outcomes 
is straightforward, but they do not easily capture time 
dependency or recurrent events in chronic or complex 
diseases such as heroin addiction. However, decision-tree 
models can be adapted to better reflect aspects of time 
dependency and/or longer term outcomes. An example 
of this is incorporation of Monte Carlo simulations, as 
was done in two of the HTA models reported [1, 23].
Other approaches that overcome the issues associated 
with modelling long-term or chronic conditions with dis-
crete health states include cohort models or Markov mod-
els. In this type of model, patients are in one of a number 
of finite health states, which are mutually exclusive and 
represent clinically and economically important events. 
Movements between health states are determined by tran-
sition probabilities. Decision-tree models, cohort models 
and Markov models are favoured by HTA agencies for 
their simplicity of construction and analysis. However, the 
transition probability of moving from one disease state 
to another is independent of the patient’s disease history, 
and there is a fixed cycle time before a patient is eligible 
to move into a new state. These are potentially impor-
tant limitations in opioid dependence, as transitions are 
affected by individual patient characteristics, previous 
behaviour and treatment history [22]. Ways to address 
these limitations within the Markov/cohort framework 
include using additional health states to account for dis-
ease history (as long as the number of states does not 
become too cumbersome), or the transition probabilities 
can be made time-dependent [1].
Patient-level simulation models such as dynamic mod-
els and Monte Carlo simulations can also be used to 
capture stochastic variation in outcomes between indi-
viduals, and can take account of heterogeneity in factors 
such as demographic characteristics and previous his-
tory. Their main deficiency is lack of transparency with 
regard to data inputs and how they are combined within 
the model, coupled with the prolonged time taken to run 
sensitivity analyses [1].
Dynamic models, used by three studies identified in 
this review [12, 20, 21] to evaluate population effects 
associated with needle sharing, allow internal feedback 
loops and time delays that permit the modelling of health 
changes across entire populations or systems. They are 
well established in the study of infectious disease trans-
mission through populations [1].
Four studies identified in this review used Monte Carlo 
simulation [1, 22–24], and a further study used it for the 
sensitivity analyses [14]. However, these types of mod-
els are known to produce different results from those 
of static models, and the direction of the results may be 
unpredictable compared with models such as decision 
trees or Markov models. Comparisons of results between 
dynamic models and static models cannot easily be made. 
As a result, dynamic models may not be accepted by HTA 
assessment groups, as noted in a systematic review and 
economic evaluation of methadone and buprenorphine 
for the management of opioid dependence in 2007 [1].
A limitation of our review is that it did not include 
health economic models based solely on data from the 
duration of a randomised controlled trial, i.e. those that 
did not extrapolate beyond the trial duration. Whilst this 
does represent another possible modelling approach, the 
short duration of such trials means it is unlikely to be 
suitable for modelling a chronic condition such as non-
prescription opioid dependence.
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Fig. 4 Overview of outcomes and costs considered. HIV human immunodeficiency virus, LYG life-years gained, QALY quality-adjusted life-years
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Model parameters such as time horizons were reflected 
in the modelling approach. Time horizons in decision 
analytical models ranged from 6 months to 1 year while 
cohort/simulation models ranged from 5 years to a life-
time. Modelling guidelines [30] recommend that the time 
horizon of a model should be long enough to capture 
all important differences in costs or outcomes between 
two or more treatments or between treatment and no 
treatment. Both models used in NICE HTA appraisals 
were 1 year in length [1, 23]. As opioid dependence may 
require long-term or life-long treatment [4], longer time 
horizons are likely to be more appropriate for models 
of opioid dependence, so that a realistic picture of life-
time costs and benefits of treatment can be adequately 
presented.
The model inputs reflected the perspective taken. Costs 
included in the economic evaluations were mainly those 
relating to healthcare service costs associated with opi-
oid agonist therapy, including costs to primary care ser-
vices and hospital services. Wider societal costs, such 
as costs of drug-related crime, disorder and antisocial 
behaviour, and loss of productivity in the workplace, 
were included in some form in only a few of the models. 
Impacts on family and social networks have not been 
included in any model. Costs to the individual patient, 
such as out-of-pocket costs, the costs related to prema-
ture death, drug-related illness and the loss of earnings 
through criminality/imprisonment, sickness, temporary 
or permanent unemployment and reduced educational 
attainment are also not routinely included in economic 
models. This may be because these types of costs are not 
ordinarily included in economic evaluations of healthcare 
interventions, so comparability with other interventions 
would be hampered if they were included. Indeed, HTA 
groups around the world have varying guidelines regard-
ing costs to be included in a reference case for economic 
evaluations. In Sweden and The Netherlands, all relevant 
direct and indirect costs and revenues for treatment and 
ill health, irrespective of the payee, should be considered 
[29, 32]; in Norway, unrelated medical and non-medical 
costs should not be included [31]; in the UK a broader 
perspective on costs (beyond the NHS and Personal 
Social Services) may only be considered in exceptional 
circumstances [30]; while in Australia, PBAC mainly con-
siders the costs of providing health care resources but 
may also consider costs and cost offsets of non-health 
care resources, although these might not be as influential 
in decision making as health care resources [33]. In the 
treatment of drug addiction, consistent omission of wider 
costs and benefits in the reported models means that 
the impact of effective maintenance treatments will not 
be fully captured; this will under-estimate the benefit of 
maintenance treatment to society. For example, reducing 
the spread of HIV will benefit non-drug users who will 
avoid HIV infection [11, 12] and is an important societal 
impact of maintenance treatment. In the US, total life-
time treatment cost for HIV based on new diagnoses in 
2009 was estimated to be $16.6 billion [34].
The most common form of evaluation was cost-utility 
analysis, with an outcome measure of the number of 
QALYs gained. This may reflect the preference of HTA 
agencies for this type of analysis as it incorporates the 
value placed on health effects by society [30, 33]. How-
ever, there are limited data sources available for utility 
weights for substance abuse. Including the impact on 
quality of life is important because substance abuse is 
associated with significant co-morbidities and personal 
and social impacts, all of which should be considered 
when estimating the benefit of maintenance treatment. 
Thus, QALY weights should take account of reduc-
tions in health due to the disease of addiction itself and 
the impact of treatment on quality of life. In this review, 
only one source was available where the standard gam-
ble method was used with members of the general pub-
lic to obtain QALY weights for health states in substance 
abuse [16]. Choice-based preference measures to capture 
the value of health-related quality of life impacts are rec-
ommended by HTA groups such as NICE in the UK [30], 
PBAC in Australia [33] and HTA groups in European 
countries such as Norway [31], The Netherlands [29] 
and Sweden [32]. However, with addiction therapies and 
services the question could be asked about whose values 
should be used. Members of the public valuing vignettes 
developed by patients may be skewed by moral judge-
ments, so perhaps people who have recovered from drug 
addiction might be the best-informed group.
Conclusions
This systematic review identified 18 economic modelling 
studies in non-prescription opioid dependence report-
ing a range of modelling approaches. There appears to be 
no single standard emerging as the preferred approach 
and there are a number of advantages and disadvantages 
to the different modelling approaches, some of which 
can be overcome using advanced modelling techniques. 
These factors, together with acceptability to HTA agen-
cies, need to be considered when selecting a model struc-
ture for economic evaluation of a new therapy indicated 
for the maintenance treatment of non-prescription opi-
oid dependence.
The most common evaluation type was cost-utility 
analysis reporting the cost per QALY gained (11/18 
models), reflecting the preference of HTA agencies 
for this form of evaluation, although the data on utility 
weights are limited. Typical outcomes include mortality 
and treatment retention. However, wider societal costs 
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such as the cost of crime (expenditure by the criminal 
justice system in dealing with crimes committed, and 
cost consequences for the victims of crime), productiv-
ity, employment impacts, transmission of HIV and HCV 
and costs of treatment borne by patients (for example, 
transportation costs and value of time spent receiving 
treatment) are not typically included in health economic 
modelling. Given the wide ranging impact of illicit opioid 
abuse on the workplace, the healthcare system, and in the 
communities, including these non-typical costs may help 
present a more complete story of the economic burden.
This review identified some key elements that could 
form a standard framework and guide for future models, 
such as:
  • Selecting a modelling approach that is able to capture 
the complexities of opioid use, allow for transitions to 
be affected by past behaviour and include transmis-
sion of HIV and other drug-related infectious dis-
eases;
  • Selecting a time horizon that is long enough to cap-
ture the impact of treatment and disease on patients 
in this chronic condition;
  • Inclusion of societal consequences associated with 
heroin use that also have important economic con-
sequences;
  • Capturing the impact of disease and treatment-
related health-related quality of life/utility specific 
to this patient population through appropriately 
sourced and valued health states.
The range of modelling approaches found in the litera-
ture could not easily be compared in terms of quality but 
the evidence does indicate that there is currently no sin-
gle standard emerging as the preferred approach. Indeed, 
a number of the methodological approaches taken in dif-
ferent modelling studies could be used together to begin 
to build a framework for future models in this disease 
area. Furthermore, some of the disadvantages of cur-
rent model structures could be overcome by using more 
advanced modelling techniques or choosing a different 
model approach. We propose that to develop a future 
model for the pharmacoeconomic evaluation of opi-
oid agonist interventions, researchers should first iden-
tify the most robust model currently available, replicate 
the model, and then extend that model in terms of the 
range of inputs described above. Such a model should be 
applicable to a range of scenarios, e.g. intervention ver-
sus no intervention, comparison between interventions, 
changes over time, societal impact. Providing access to 
the model and the associated model code to the health 
care community could stimulate future dialogue and 
make it easier to recognise the strengths and weakness of 
different modelling approaches.
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